Fig 1.

ICP0 colocalizes with SUMO-modification defective PML.I. (A) ICP0 and endogenous PML colocalize in control HepaRG cells expressing an anti-luciferase shRNA (shLuci). ICP0 also forms foci in PML depleted HepaRG cells (shPML). Cells were infected with wt HSV-1 at an MOI of 2 in the presence of MG132 and costained 4 h later for ICP0 and PML. (B) ICP0 colocalizes more efficiently with EYFP-PML.I than EYFP.PML.II or EYFP.PML.IV when these proteins are expressed in cells depleted of endogenous PML (shPML). Cells were infected as described above and stained 4 h later for ICP0 only. (C) PML.I SUMO-modification deficient mutants also colocalize with ICP0. Cells (shPML) expressing the indicated EYFP-PML.I isoform mutants were infected and stained as in panel B. All images are single-plane projections of short z-stacks. (D) Quantification of ICP0, PML, and colocalizing ICP0/PML foci. The ratios of colocalizing compared to noncolocalizing foci, as indicated by the shaded bars, are presented, based on the data of Table 1.